- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.09. | BioAdaptives, Inc.: BioAdaptives Confirms First Commercial Orders of XcellaraHeart and Outlines Capital Restructuring Progress | 462 | ACCESS Newswire | Initial XcellaraHeart orders ship next week, marking the commercial launch of the Xcellara cellular wellness platform; Company prepares XcellaraResilience for October launch and highlights the retirement... ► Artikel lesen | |
| 31.08. | BioAdaptives, Inc.: UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem | 294 | ACCESS Newswire | Former UFC middleweight champion and current broadcaster will help promote MyndSystem as part of a disciplined day-and-night performance routine LAS VEGAS, NV / ACCESS Newswire / August 31, 2026 / BioAdaptives... ► Artikel lesen | |
| 19.08. | BIOADAPTIVES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| BIOADAPTIVES Aktie jetzt für 0€ handeln | |||||
| 14.08. | BIOADAPTIVES, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 13.08. | BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update | 359 | ACCESS Newswire | Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure. LAS VEGAS, NV / ACCESS Newswire / August 13, 2026 / BioAdaptives, Inc. (OTCID:BDPT)... ► Artikel lesen | |
| 12.08. | BioAdaptives, Inc.: BioAdaptives Inc. Introduces XcellaraHeart: the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal | 313 | ACCESS Newswire | The flagship product of the new Xcellara cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating... ► Artikel lesen | |
| 04.08. | BioAdaptiveas, Inc.: BioAdaptives Explains the Scientific Basis of the Dual-Action Xcellara "Supply and Direction" Platform | 277 | ACCESS Newswire | The Platform integrates clinically researched stem and progenitor cell mobilization with ingredients that have been studied for their roles in tissue signaling pathways. LAS VEGAS, NV / ACCESS Newswire... ► Artikel lesen | |
| 03.08. | BioAdaptives, Inc.: BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart Cellular Wellness Formula | 278 | ACCESS Newswire | Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives,... ► Artikel lesen | |
| 30.07. | BioAdaptives, Inc.: BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor | 687 | ACCESS Newswire | Strategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches. LAS VEGAS, NV / ACCESS Newswire / July 30, 2026 / BioAdaptives... ► Artikel lesen | |
| 29.07. | BioAdaptives, Inc.: BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem Nootropic Platform | 891 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital storefront... ► Artikel lesen | |
| 23.07. | BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches | 227 | GlobeNewswire (Europe) | LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial... ► Artikel lesen | |
| 16.07. | BioAdaptives Inc.: BioAdaptives Outlines Xcellara Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness | 219 | GlobeNewswire (Europe) | LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara cellular wellness platform ahead of the August 1,... ► Artikel lesen | |
| 15.07. | BioAdaptives Inc.: BioAdaptives Inc. Announces XcellaraHeart, a Cardiovascular Wellness Formula Built on Xcellara's Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells | 186 | GlobeNewswire (Europe) | LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara line of stem cell mobilization supplements, today announced the upcoming commercial... ► Artikel lesen | |
| 25.06. | BioAdaptives Inc.: BioAdaptives Completes MyndSystem Platform with TruShield Certification of MyndRenew, Securing Full WADA Compliance for Professional Athletes and Expanding Market Opportunity | 426 | GlobeNewswire (Europe) | LAS VEGAS, June 25, 2026 (GLOBE NEWSWIRE) -- via IBN - BioAdaptives, Inc. (OTC: BDPT), the parent company of MyndSystem, today announced that its nighttime repair formula, MyndRenew, has received... ► Artikel lesen | |
| 20.05. | BioAdaptives Inc.: BioAdaptives Launches MyndSystem Website - The First Supplement Platform Designed to Support Both Daytime Cognitive Performance and Overnight Brain Recovery | 1 | GlobeNewswire (USA) | ||
| 06.05. | BioAdaptives Inc.: BioAdaptives, Inc. Launches MyndRenew to Complete the 24-Hour Brain Performance Cycle | 233 | GlobeNewswire (Europe) | LAS VEGAS, May 06, 2026 (GLOBE NEWSWIRE) -- via IBN - More than 1 in 3 American adults report insufficient sleep - a deficit that research increasingly links to measurable declines in next-day cognitive... ► Artikel lesen | |
| 28.04. | BioAdaptives Inc.: BioAdaptives introduces MyndSystem, an integrated Neuro-Performance & Repair system for day and night | 1 | GlobeNewswire (USA) | ||
| 14.04. | BIOADAPTIVES, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | BIOADAPTIVES, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 07.10.25 | BioAdaptives Inc.: BioAdaptives Announces Commercial Launch of MyndMed Following Successful Pilot Testing | 262 | GlobeNewswire (Europe) | LAS VEGAS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT) today announced the commercial availability of MyndMed, a next-generation cognitive-support dietary supplement... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| ELECTRA THERAPEUTICS | 13,500 | +1,89 % | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | +0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | 0,00 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | +0,04 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern |
Das Unternehmen BIOADAPTIVES INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOADAPTIVES INC finden Sie auf Wallstreet Online.